Researchers spotlight a basket of 'good' response rates for the next ADC in Seattle Genetics' pipeline
In August 2017, Seattle Genetics opted into a development partnership for an antibody-drug conjugate developed by Genmab as part of a collaboration seven years in the making. A year and a half later, researchers have pulled the curtain back on some early results that might justify their enthusiasm for tisotumab vedotin.
In a Phase I/II trial involving 147 patients — spanning 6 different cancer types — who have become resistant to an average of three types of prior treatments, the ADC is found to yield responses in a “significant minority,” meaning their tumors either shrank or stopped growing. The responses lasted an average of 5.7 months, with the top of the range reaching 9.5 months, according to the research team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.